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Abstract. The advent of Omics technologies has been key to the molecular subclassification of urothelial bladder cancer. Several
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INTRODUCTION
The wealth of information resulting from the
genomics revolution has provided the opportunity to
deconvolute histology-based tumor phenotypes into
a huge number of individual molecular trait-based
phenotypes. A major challenge is to summarize such
large datasets into tumor subtypes through a new
molecular taxonomy of cancer. This effort, pioneered
in the early 2000’s in the area of breast cancer, has
expanded to include essentially all tumor types in
recent years through the massive genome sequencing
efforts carried out under the auspices of the The Cancer
Genome Atlas (TCGA) and the International Cancer
Genome Consortium (ICGC) projects. Urothelial blad-
der cancer (UBC) has been a relative latecomer to these
studies. In the last few years, the efforts of both indi-
vidual research groups and the TCGA consortium have
led to several proposals for molecular subclassification
that herald promise for clinical application in multiple
aspects of patient management.
In UBC, the Lund group was first to use expression
profiling of tumors covering a wide spectrum of the
disease to propose of a molecular taxonomy classifi-
cation. Subsequent studies - either biology-based or
multidata platform-based - rapidly showed remark-
ably consistent evidence supporting the existence of
UBC subphenotypes. Most of this research has been
carried out in muscle-invasive bladder cancer. At the
same time, this work unveiled unmet needs in this
area, such as more detailed genomic analyses of non
muscle-invasive(NMI)tumors.TheTCGAPan-Cancer
integrated multidata platform analysis of 12 differ-
ent cancer types also allowed placement of the UBC
molecular subphenotypes in a broader context of cell
and tissue-specific differentiation. Issues related to
differences in genome technologies, bioinformatics
strategies/tools for genome analysis, nomenclature,
biology-based vs. clinical problem-targeted classifi-
cation - among others - arose from the independent
molecular taxonomy proposals.
In this scenario, several among us deemed that -
at this relatively early stage of development of UBC
molecular taxonomy - a Consensus meeting would
provide a useful setting to facilitate progress in the
field and stimulate collaboration. The meeting held
at the Spanish National Cancer Research Center-
CNIO (Madrid, Spain) on March 24, 2015 brought
together all of the groups having proposed genome-
based molecular subtyping of UBC in the recent years.
The main aims were to:
1) present the sample selection and methodological
strategies used to achieve the different molecular
taxonomies;
2) discuss the overlap existing among the different
molecular taxonomies;
3) develop a cooperative strategy to optimize the
reported classifications; and
4) join efforts to validate the optimized classifica-
tion in prospective studies.
What follows is a summary of the presentations,
discussions, and consensus agreement including some
suggestions to the investigators working in this field.
THE TCGA PROJECT
S. Lerner and K. Hoadley presented the work of the
TCGA bladder cancer project. The initial TCGA report
included the interim integrated genomic analysis of the
first 131 patients [1]. Chemotherapy-naive, invasive
urothelial cancers were analyzed for somatic muta-
tions, DNA copy number variants (CNVs), mRNA and
microRNA expression, protein and phosphoproteins
(reverse phase protein arrays, RPPA), and DNA methy-
lation. Other histologies were excluded from the study.
The genetic information was integrated with compre-
hensive clinical and pathologic data. This invasive
tumor cohort has one of the highest somatic mutation
rates with a mean and median somatic mutation rate of
7.7 and 5.5 per megabase, similar to adenocarcinoma
and squamous cell carcinoma (SCC) of the lung and
melanoma. There were 32 significantly mutated genes
(SMGs) involved in multiple pathways including cell
cycle regulation (93% of tumors), chromatin remod-
eling (76%), DNA damage response, transcription
factors, and receptor tyrosine kinase (RTK)/RAS/PI3K
(72%) signaling pathways. Four SMGs involved in epi-
genetic regulation (ARID1A, MLL2, KDM6A, and
EP300) were mutated in up to one fourth of the
tumors. One-third of the tumors were characterized by
cancer–specific DNA hypermethylation [1]. An addi-
tional 281 invasive tumors are in the pipeline and
the TCGA team is currently analyzing the complete
data set with the expectation of publishing an updated
comprehensive integrated analysis. Mutation data are
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available on all 412 samples (including the first 131)
and 54 SMGs have been identified, including 26 that
were reported in the first paper. As observed in the
first 131 tumors, many of these SMGs have not pre-
viously been described in bladder cancer. Combining
CNV and somatic mutations, 69% of tumors harbor
one or more potentially actionable targets. Three muta-
tion/CNV groups were identified and characterized as:
1) “Focally amplified” - enriched in focal CNVs (e.g.
3p loss/PPARG) and MLL2 mutations; 2) enriched
for TP53 and RB1 mutations, and E2F3 amplifica-
tions; and 3) papillary histology, FGFR3 mutant, and
CDKN2A-deficient.
Unsupervised clustering of mRNA, miRNA and
RPPA data suggested the existence of four expression
clusters, 3 of which were fully characterized as follows.
Cluster I was enriched with papillary morphology
and FGFR3 dysregulation through mutations, ampli-
fications, gene fusions, overexpression, and miRNA
regulation. Clusters I and II expressed high HER2
(ERBB2) and estrogen receptor beta signaling signa-
tures, sharing features with Luminal A breast cancers.
Cluster III shows similarities to other TCGA tumor
types, including basal-like breast and SCC of the head
and neck and the lung [1]. Tumors in this cluster
show high expression of KRT14 and CD44, sugges-
tive of stem cell markers, similar to the basal subtype
of bladder cancer originally reported by the Baylor
College of Medicine group [2, 3] and to the sub-
type described by Sjödahl et al. which was associated
with the worst prognosis compared to the other sub-
types they described [4]. This was confirmed with a
recent TCGA pan-cancer analysis of 12 tumor types
and 6 data types, which stratified the bladder cancer
cohort into 3 groups. A small subset was similar to
lung adenocarcinoma, a second subset - with most
of the cluster III and squamous samples - clustered
with the head and neck and lung SCC, and the third -
which contained the majority of tumors - was unique
to bladder cancer and had the best prognosis com-
pared to the two other subtypes [5]. Expression cluster
IV comprised the smallest number of patients and
shared features similar to cluster III but also con-
tained features of the surrounding stroma and muscle.
Whole exome sequencing and copy number variation
have been incorporated into the expression profiling
in the expanded cohort of 412 tumors. The basal clus-
ter had a higher proportion of females and displayed
high expression of immune response genes and squa-
mous epithelial markers, suggesting that this particular
phenotype may respond to therapy targeting immune
checkpoint inhibition.
The complete data set will increase the power to
detect additional low frequency events (6), validate the
cluster analyses, test hypotheses regarding chemother-
apy resistance, and provide a host of translational
opportunities for functional validation and targeted
therapy trials. Outcome analyses were deliberately not
included in the analysis of the first 131 tumors as the
follow up data were not mature. It is expected that all
this information will be included in the final analysis
of the full cohort.
THE LUND MOLECULAR TAXONOMY
STUDIES
M. Höglund and his group presented a summary of
the work carried out in Lund. A first attempt to clas-
sify UBC in terms of genome wide gene expression was
made by Lindgren et al. and included both invasive and
NMI tumors [7]. This analysis of 144 samples identi-
fied two major molecular subtypes named MS1 and
MS2. The split between MS1 and MS2 clearly divided
the samples into grade 1 or 2 (MS1) and grade 3 (MS2)
(WHO1999), and between Ta (MS1) and ≥T2 (MS2)
tumors. T1 cases were distributed almost equally
between the two subtypes. The MS1 and MS2 cate-
gories differed significantly with respect to the number
of genomic alterations, FGFR3 and TP53 mutations,
and survival. To deepen the analysis, Sjödahl et al. [8]
extended the study to include 100 Ta, 100 T1, and 100
≥ T2 tumors that made it possible to subdivide the
MS1 cases into two groups (MS1a and MS1b) and
the MS2 subtype into five groups (MS2a1, MS2a2,
MS2b1, and MS2b2.1 and MS2b2.2). An extensive
biological interpretation of gene expression data iden-
tified biological themes including immune, late cell
cycle, keratin, and RTK signatures that determined
the data structure. In addition, a signature associated
with FGFR3 expression was derived. Based on histol-
ogy, gene signature biology, and FGFR3, PIK3CA, and
TP53 mutations, three major subtypes or UBC were
defined: urobasal (Uro) (MS1a, MS1b, and MS2b2.1),
genomically unstable (GU) (MS2a1 and MS2a2), and
SCC-like (SCCL) (MS2b2.2). In addition, an “infil-
trated” group was recognized in which non-tumoral
inflammatory transcripts dominated expression pat-
terns. A subset of the urobasal tumors (MS2b2.1)
showed a “progressed phenotype” with increased cell
cycle activity and expression of basal cell related ker-
atins in suprabasal cell layers. This group corresponded
largely to invasive tumors and was named urobasal B
to distinguish it from urobasal A that were NMI in
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almost all cases. An important finding was that molec-
ular subtypes transcended pathological staging. For
instance, all four subtypes (UroA, UroB, GU, and
SCCL) were detected among T1 tumors and no fun-
damental differences were observed between invasive
and NMI GU cases [8].
Lindgren et al. extended these analyses by combin-
ing gene expression data with array-CGH data for 146
cases [9]. This revealed that Uro tumors show low num-
bers of genomic alterations, typically loss of chromo-
some 9 and gains of 1q, whereas GU and SCCL tumors
showed complex changes with frequent focal genomic
alterations, i.e. 6p22 (E2F3/SOX4) amplifications. By
an integrated approach, two major genomic circuits
were found to participate in UBC: a FGFR3/CCND1
circuit operating in Uro tumors and an E2F3/RB1 cir-
cuit in GU tumors. For the SCCL subtype, no specific
circuit could be established. In addition, homozygous
deletions of CDKN2A (9p21) were found to represent
a progression event among Uro tumors.
To validate the gene expression results using
immunohistochemistry (IHC), a panel of antibodies
detecting 20 proteins was used providing further sup-
port to the UroA, UroB, GU, and SCCL subtypes [10].
Urobasal tumors commonly exhibited a basal mem-
brane with KRT5+ and P-CAD+ basal cells and TP63+
transitional cells; GU tumors were KRT5−, P-CAD−,
and TP63− but E-CAD+ and ERBB2+; and the SCCL
tumors were KRT5+ and P-CAD+ throughout the
tumor. Using IHC, the “infiltrated” group was shown
to be composed of either GU or SCCL tumor cells,
infiltrated with immune cells. The previously described
genomic circuits could be assessed at the IHC level to
identify Uro and GU cases. More recently, the IHC-
based classification system described by Sjödahl et al.
[9] was applied to 165 T1 tumors, showing that molecu-
lar subtype (Uro vs. GU and SCCL) had a major impact
on progression rates, supporting the clinical value of
the taxonomy [11].
DNA-methylation was assessed by Lauss et al.
[12] in 149 UBC and showed that the MS1 and
MS2 subtypes differed significantly with respect to
methylation patterns. Epigenetic structure was fur-
ther analyzed in Aine et al. [13], showing that UroA
tumors exhibited a methylation pattern distinct from
the remaining subtypes and that the majority of GU
cases revealed a Polycomb (PCR1/2)-related methyla-
tion pattern. The compiled genomic (array-CGH) and
DNA-methylation data supports the relevance of the
urobasal, GU, and SCCL bladder cancer subtypes.
The subtype-specific gene expression profiles
described above were assigned to transcription factor
regulatory modules by use of publically available
Chip-Seq data and IHC [14]. Tumors of the SCCL sub-
type overexpressed genes enriched in STAT3 binding,
showed phospho-STAT3 up-regulation, and displayed
down-regulation of PPARG, RXRA, FOXA1, and
GATA3 transcription factors as well as their target
genes. The urobasal subtype showed up-regulation of
PPARG, RXRA, FOXA1, and GATA3 - and their tar-
get genes - as well as expression of anterior HOXA
and HOXB genes, and up-regulation of HOXA2 tar-
gets. The major regulatory axis operating in the GU
subtype was PLK1-FOXM1, inducing a strong prolif-
erative activity. Hence, the three major subtypes, Uro,
GU, and SCCL may be explained by the activity of
specific gene regulatory networks, either involved in
urothelial differentiation or shared with other tumor
types [14].
Using the bladder cancer TCGA data (234 invasive
tumors) as a reference set, the Lund group evalu-
ated four published gene expression-based bladder
cancer classification systems: the two-tiered Univer-
sity of North Carolina (UNC), the three-tiered MD
Anderson (MDA), the four-tiered TCGA, and the
five-tiered Lund [15]. This analysis showed that a
hierarchical relationship among the UNC, MDA, and
TCGA classifications systems exists and that substan-
tial biological subgroup heterogeneity remains at the
highest resolution. Thus, a six-tiered classification sys-
tem was reached including: a SCCL/UroB group, a
GU group, an urobasal group, two groups with slightly
different profiles emerging from the “infiltrated” cate-
gory, and a new variant tentatively classified as “small
cell/neuroendocrine-like”. Subtype assignments were
validated by genomic alterations (chromosomal aber-
rations) and gene mutations [15].
Because the Lund group based their classification
on both invasive and NMI cases and some of the
subtypes cluster close together in pure invasive set-
tings, they conclude that gene expression phenotypes
converge upon progression. However, subtype-specific
gene expression signatures are still present in invasive
tumors.
THE UNIVERSITY OF NORTH CAROLINA
CLASSIFICATION
B. Kim’s strategy focused on the analysis of inva-
sive tumors. Using K2 consensus clustering, a robust
classification of tumors enriched in basal (KRT5/6
and CD44) vs. luminal (PPARG, GATA3, KRT20,
and UPK2) subtypes was reached [16]. A signature
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including 47 genes (BASE47) was generated by
prediction analysis of microarrays (PAM) that was
associated with outcome in 3 independent patient
series. The basal subtype revealed similarities with the
basal subtype of breast cancers, as demonstrated by
applying the PAM50 signature to the UBC datasets.
This group contained a claudin-low subgroup, as
defined in breast cancer, that was enriched in epithelial-
mesenchymal transition (EMT) and tumor initiating
cell markers. Patients whose tumors were of the
claudin-low subgroup had an outcome similar to that of
patients in the “basal” category. Using pathway analy-
sis and GSEA, a significant enrichment in genes related
to inflammatory cell infiltration and immune check-
point was observed in the basal subgroup and, more
specifically, among the claudin-low tumors. The RNA-
defined basal subgroup was also selectively enriched
in RB pathway gene alterations while the luminal sub-
type was enriched in FGFR3 and TSC1 mutations. By
contrast, there was no enrichment of TP53 pathway
alterations. The basal group was significantly more
common among women [16].
THE BAYLOR COLLEGE OF MEDICINE
(TUMOR DIFFERENTIATION)
CLASSIFICATION
K. Chan presented an update of his group’s recent
work on bladder cancer subtyping based on urothe-
lial cell differentiation [2, 3, 17]. A KRT14/Thy-
1/CD44-positive self-renewing stem cell population
was proposed to give rise to a partially differentiated
KRT5/KRT17/CD44-positive progeny that is thought,
in turn, to acquire KRT8/18 expression and terminally
differentiate into luminal cells expressing uroplakins
and KRT20. Knowledge on the normal urothelium dif-
ferentiation program was thus used to classify tumors.
The KRT14+ group (basal subtype) was characterized
as having poor prognosis in multiple patient cohorts [2]
and these KRT14+ basal tumors are resistant to neoad-
juvant cisplatin-based chemotherapy in a small patient
cohort [18]. An 18-gene classifier containing differenti-
ation markers was applied to the TCGA series, showing
that basal tumors were enriched in stem/progenitor
urothelial cell markers such as KRT14/5/17, CD44 and
CD49f,aswellassignalingmolecules includingEGFR,
JAK2, and STAT3. These findings echo an independent
report from the CIT group demonstrating that EGFR
signaling is functionally important in their basal-like
tumors (see below) [19] and further support studies
from Lund and MDA groups that STAT3 signaling
is enriched in their basal tumors [20] (see above and
below). Patients with tumors classified as “basal” had
a significantly worse survival than those that were
“differentiated” and the P-values generated from this
18-gene classifier were more significant than those
resulting from clustering methodologies utilized by
TCGAorothergroupstocorrelatewithclinicaloutcome
[17]. Baylor College of Medicine’s defined “basal”
tumors were exclusively in cluster III/IV of the TCGA
and overlapped with “basal” tumors as defined by the
MDA group (see below). Similarly, the “differentiated”
tumors overlapped well with clusters I and II of the
TCGA classifier and with the “luminal” group of MDA
[1,20].Bycontrast, thep53-likegroupofMDAwassim-
ilarly split between “basal” and “differentiated” tumors
(see below). A comparison was also performed with the
classification of Lund: the “basal” group was modestly
enriched in a subset of the Urobasal A tumors (Ms1a)
and in the “infiltrated” group, and strongly enriched
among the Urobasal B and SCCL tumors. By con-
trast, the“differentiated”groupwasenrichedamongthe
Ms1b subgroup of Urobasal A tumors and the Ms2a.2
subgroup of GU tumors. Interestingly, all Ms2a.1 GU
tumors were “differentiated” Classification based on
urothelialcelldifferentiationdemonstratedasignificant
association with survival, and the basal subtype cor-
related well with clustering methodologies by TCGA
(Cluster III/IV) and CIT [1, 19]. Nonetheless, it remains
unresolved why the urothelial differentiation cluster-
ing method showed that basal tumors are more, or at
least equally, resistant to chemotherapy while the MDA
group claims otherwise.
THE MD ANDERSON SUBTYPES
To identify intrinsic subtypes, D. McConkey and
the group at MDA modeled their approach after the
pioneering breast cancer subtyping studies of Perou
et al. [21, 22]. They generated genome wide mRNA
expression profiling data from a cohort of 142 flash-
frozen invasive and NMI UBC using Illumina chips
[20]. The results revealed the presence of three dis-
tinct clusters; further analyses of the significantly
differentially expressed genes defining each cluster
revealed that they were enriched with biomarkers
that had previously been implicated by Perou’s group
and others as characteristic of the basal-like (KRT5,
KRT14, CDH3, CD44) and luminal (KRT20, CD24,
FOXA1, GATA3, ERBB2, ERBB3) intrinsic subtypes
of breast cancer [20, 23, 24]. One of the subtypes was
defined by a gene expression signature characteristic of
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active wild-type p53, therefore being designated “p53-
like” [20]. Functional studies demonstrated that active
DNp63a and STAT3 were involved in the control of
basal gene expression, whereas PPARG was respon-
sible for luminal gene expression, and DNp63a and
PPARG antagonized each other. Tumors within the
p53-like subtype were mostly resistant to neoadjuvant
cisplatin-based combination chemotherapy [20].
The MDA group compared their subtype calls with
those of the groups at the University of Lund [8],
TCGA [1], and the UNC [16], using shared datasets.
Overall, there was close concordance among the
classifications. The MDA “basal” tumors corre-
sponded well with the Lund “SCC-like” subtype,
TCGA’s Clusters III (“squamous”) and IV, and UNC’s
“basal-like” tumors. The MDA “luminal” tumors cor-
responded with the Lund “genomically unstable”,
TCGA cluster I and UNC’s “Luminal”, while the MDA
“p53-like” tumors matched the Lund “infiltrated”,
TCGA Cluster II, and merged in the “luminal” UNC
subtype [12, 13, 20, 23]. Because each group used very
distinct approaches to identify their subtypes, the fact
that all reached similar conclusions strongly suggests
that the subtypes are highly reproducible and biologi-
cally relevant, regardless of how they are named.
Many investigators now prefer consensus cluster-
ing to unsupervised hierarchical clustering to identify
subtypes of cancer because it assesses the stability of
clusters based on multiple re-samplings. Therefore,
the MDA group investigated how their calls would
have changed had they applied consensus clustering, as
opposed to other clustering methods, using the TCGA
RNAseq dataset (n = 128, log2-transformed) as a refer-
ence. They identified the top 5000 most variable genes
as measured by median absolute deviation and median
centered the data and used this subset for consen-
sus clustering (specifically, agglomerative hierarchical
clustering). Area under the curve analyses identified
four clusters as the optimum but one of the clusters
onlycontainedone tumor, leading themtoconclude that
three groups would have been more biologically rea-
sonable.Whentheanalyseswereperformedusingk = 5,
TCGA’s four clusters were reproduced almost exactly,
and comparison of the calls again revealed excellent
concordance with the MD Anderson subtypes.
THE CIT “BASAL-LIKE” TUMOR
CLASSIFICATION
F. Radvanyi and his colleagues from the CIT consor-
tium (Institut Curie, Henri Mondor and Foch hospitals,
Institut Gustave Roussy, CEPH, La Ligue Contre le
Cancer) focused on the “basal-like” tumor subgroup
because it was the largest homogeneous group iden-
tified by various unsupervised methods to classify
invasive bladder cancer based on transcriptome data
[19]. In a joint analysis of 7 datasets of invasive tumors,
more advanced cases were over-represented among the
“basal-like” tumors. Survival analyses showed worse
outcome for this group of patients, independently of
stage and grade, lymph node, and metastatic status. The
survival curves of patients with basal-like tumors were
very different from other bladder cancer patients, with
most of the death events occurring within one year after
diagnosis. At the level of DNA alterations, this group
was characterized by significantly more EGFR gains or
amplifications, FHIT deletions, and TP53 mutations; at
the transcriptomic level, an enrichment of EGFR path-
way activation was identified. In agreement with this
observation, EGFR phosphorylation was higher in the
basal-like subgroup. This led to testing in vitro and
in vivo the sensitivity of bladder cancer cells to the
EGFR inhibitor erlotinib. For this purpose, a particular
effort was made to identify relevant preclinical mod-
els recapitulating human primary basal-like bladder
tumors. Using a transcriptomic signature derived from
human invasive bladder cancer datasets, they identified
11 human bladder cancer cell lines - out of 22 - dysplay-
ing a basal-like profile [19]. In addition, they showed
that tumors induced by N-butyl-N-(4-hydroxybutyl)
nitrosamine in mice, a commonly used model of
chemical bladder carcinogenesis, recapitulated key
molecular features of the human basal-like tumors
includingtheautocrineactivationoftheEGFRpathway.
In these models, erlotinib treatment showed anti-tumor
efficacy and the basal-like phenotype was predictive
of erlotinib response. This study provided, in vari-
ous preclinical models, the first proof-of-concept that
anti-EGFR therapies could be effective to treat human
basal-like bladder cancers [19].
In another study, they went on to use Independent
Component Analysis (ICA), an approach allowing a
gene to be placed in multiple pathways, a feature that
relates better to biological functions [25]. Using this
strategy, they could characterize cancer subtypes and
identify candidate genes to be involved in different
pathways. The “basal” subgroup was found to cor-
respond to the TCGA cluster III and it was mainly
enriched in the interferon response pathway, had a high
content in myofibroblasts and low T and B lymphocyte
content. Smooth muscle and T and B lymphocytes were
mainly enriched in cluster IV. Invasive cancers could
be divided into two groups according to the urothelial
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differentiation component. Both clusters I and II pre-
sented an urothelial differentiation program in contrast
to clusters III and IV. By combining ICA of tran-
scriptome and copy number data, they could predict
that PPARG was an oncogene for molecularly dif-
ferentiated tumors. This was confirmed by functional
analyses [25]. When they applied ICA to a Pan-Cancer
cohort, some components were found in all cancer
types (i.e. lymphocytes, cell cycle). By contrast, others
were found only in UBC (i.e. urothelial differentiation
and the carcinoma in situ pathway).
Radvanyi also discussed different strategies for
identifying the basal-like subgroup comparing a 40
gene-based transcriptomic signature and IHC based
on two antibodies recognizing KRT5 and KRT6 as a
positive marker of the subgroup and FOXA1 as a neg-
ative marker [19] (see below). In their studies, an 85%
agreement was found between both techniques.
MECHANISTIC INSIGHTS INTO THE
CONTROL OF “BASALITY”
As indicated above, all the classifications included
a set of tumors expressing basal or SCCL markers and
F. X. Real reviewed the evidence from various clas-
sifications in search of putative transcription factors/
networks that might be involved in the activation of
the various molecular sub-phenotypes. There has been
extensive work pointing to genes involved in urothe-
lial differentiation, including FOXA, GATA, PPARG,
ELF3, and IRF1 [26–28]. FOXA1 and GATA3 were
enriched among tumors in TCGA clusters I and II
and depleted from clusters III and IV. STAT3 and
DNp63a have been proposed as regulating the basal
phenotype, though less is known regarding the direct
transcriptional regulation of the “basal” program.
Work was presented pointing to the participation of
FOXA and GATA proteins in the repression of the
EMT and of a basal phenotype, and to the emergence
of these programs upon silencing or inactivation of the
GATA/FOXA proteins. Chromatin immunoprecipita-
tion followed by massive parallel sequencing showed
GATA binding to 24/47 genes from the BASE47 sig-
nature in different cell types, including urothelial cells
(P. Martinelli and F. X. Real, unpublished). GATA
and FOXA transcription factors also appeared to be
involved in cross-regulatory networks linking epithe-
lial differentiation to the transcriptional regulation of
EGFR, its phosphorylation, and the activation of down-
stream ERK and PI3K pathways [29]. The evidence
presented suggests that individual members of these
families (GATA1-6, FOXA1-3) play important roles
in different tissue types, further supported by the fact
that several of these genes are selectively mutated in
UBC [1, 30, 31].
DEFINING “INTRINSIC” BLADDER
CANCER SUBTYPES
The term “intrinsic” was first applied to the
molecular classification of breast cancers. The work
by Perou’s group demonstrated that tumor subtype
usually remained stable regardless of where or when
a given tumor was sampled [21], leading to the con-
clusion that subtype membership was an “intrinsic”
property of a given breast cancer. The original defi-
nition of “intrinsic” referred to tumor cell properties.
Although the MDA group consistently observed their
three subtypes in multiple independent datasets, this
did not necessarily indicate that all of the subtypes
were “intrinsic”. Direct measurements of cluster stabil-
ity using silhouette score analyses indicated that many
of the “p53-like” tumors in the MDA discovery cohort
were unstable, unlike the “basal” and “luminal” tumors
[20]. In addition, analyses of matched tumors before
and after neoadjuvant chemotherapy demonstrated that
many of the “luminal” tumors acquired “p53-like” fea-
tures after therapy [20]. This observation has been
confirmed in every neoadjuvant chemotherapy cohort
analyzed to date (n = 5) (W. Choi, unpublished observa-
tions). Analyses of matched primary tumors and lymph
node metastases (n = 33) indicated that basal tumors
almost never switched subtypes whereas luminal and
p53-like tumors display much more subtype “switch-
ing” (W. Choi, unpublished observations). Therefore,
basal or luminal subtype membership appears to be an
intrinsic tumor property but p53-like tumors may enter
or exit the subtype as a consequence of environmental
stimuli (“plasticity”). Finally, a working definition of
“intrinsic bladder cancer subtypes” should be agreed
upon in a future meeting.
THE CONSENSUS
The need to reach consensus about the UBC sub-
types and how they can be best defined is important
in, at least, two different areas: first, to achieve an
improved understanding of the underlying biology;
second, using this information to stratify patients
with the aim of improving management, based either
on differences in outcome or in response to therapy.
The latter aspect concerns both standard and novel,
targeted, therapies towards precision medicine.
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The above subtype descriptions clearly indicate that
all groups involved in the definition of invasive bladder
cancer subtypes identified a tumor subset character-
ized by the expression of markers typical of basal
cells in stratified epithelia, most notably KRT5/6 and
KRT14. The low expression levels of FOXA1 and
GATA3 at the RNA and protein levels also character-


















Fig. 1. Comparison of the bladder cancer classifications as they
relate to the “BASQ” (Basal-Squamous-like) consensus group. In
red background, the subtypes that are enriched in this group. Tumor
subclasses in other colors (p53-like, TCGA II, Infiltrated) comprise
samples that would be included in the BASQ group and others that
would not. Tumors in these three categories also express markers
typical of urothelial differentiation to a variable extent. In red, the
consensus definition of the “BASQ” subtype.
working on UBC, as well as in other tumor types,
have shown that there are good reagents to detect
the proteins encoded by these four genes in formalin-
fixed paraffin-embedded tissue sections. Therefore,
the group reached the consensus conclusion that a
subgroup of invasive bladder cancers can be identi-
fied as being KRT5/6+ KRT14+ FOXA1− GATA3−
(Fig. 1). In these tumors, KRT5/6 and KRT14 are
expressed broadly in cancer cells, without epithelial
compartmentalization (Fig. 2). This group appears
to be consistently associated with a poor prognosis.
Future studies should refine this molecular defini-
tion, determine the optimal techniques that can be
applied for tumor classification, as well as clinical-
pathological, and etiological associations. The Lund
data suggest that this tumor subtype can be recognized
among T1 tumors [8, 11]. Independent studies should
be useful to confirm these findings.
All attendees agreed that there is robust and concor-
dant evidence supporting the existence of an invasive
tumor subgroup with more differentiated, urothelial
features. This group is enriched in FGFR3 alter-
ations and expression of GATA3, FOXA1, KRT20, and
miR99/miR100, all of them features that are common
among the Urobasal A tumors from the Lund classi-
fication. Considering the data from NMI tumors will
likely enhance the definition of this category. How-
ever, the group felt that there was not sufficient data
to reach a consensus on the optimal molecular defi-
nition of such subgroup and that future work should
address this question in the context of both NMI and
invasive bladder tumors. This remains an important
task for future studies.
As of the other subtypes described (i.e. the GU
from Lund and the p53-like from MDA) more work is
required to determine how robust they are, how to best
define them across transcriptomic datasets, and how
to best identify them using RNA-based or IHC-based
assays.
NOMENCLATURE
The group concurred that names are important as
they deliver implicit information that should both be
helpful and clear. The designations that are proposed
here are operational, do not strictly correspond to
pathological classifications, and do not imply cell-of-
origin relationships. The group makes the following
recommendations:
1. To use Basal/Squamous-like (proposed acronym,
BASQ) to designate the tumors displaying the





Fig. 2. Basal/Squamous-like (BASQ) tumors are characterized by strong expression of KRT5/6 (A) and KRT14 (B) and low or undetectable
expression of FOXA1 (C) and GATA3 (D). By contrast to them, normal urothelial cells display strong expression of FOXA1 (E) and
GATA3 (F).
KRT5/6+ KRT14+ FOXA1− GATA3− pheno-
type. This designation responds to the fact that
there is expression of basal keratins and an
enrichment of tumors displaying histological
squamous differentiation in this subgroup [10,
19, 20] and that the molecular pan-cancer anal-
ysis assigned this group together with squamous
tumors of the lung and head and neck [5]. How-
ever, it should be emphasized that this relation-
ship is not unequivocal as not all tumors in this
group will present with histological squamous
features and some tumors with squamous features
may not fall within the group.
2. The Lund group has suggested that the pre-
viously “Urobasal” subtype defined by them
change name to “Urothelial-like” abbreviated as
Uro, and that “UroA” and “UroB” be retained as
for the previously described subtypes which, in
full, should be referred to as “Urothelial-like A”
and “Urothelial-like B” subgroups (therefore, for
the sake of clarity, it is not recommended the use
of the term “urobasal” for these subgroups).
The group agreed to reconvene in the future to update
the consensus evidence and to develop strategies for
future collaboration.
Meeting attendees: M. Aine, Y. Allory, E. Carrillo-
de Santa Pau, D. G. Pisano, K. Chan, L. Dyrskjot, A.
Hartmann, K. Hoadley, M. Höglund, W. Kim, S. P.
Lerner, N. Malats, M. Marqués, D. J. McConkey, B.
Mellado, T. C. McKee, F. Radvanyi, F. X. Real, A. de
Reyniès, G. Sjödahl.
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